Overexpression of Wilms tumor 1 gene as a negative prognostic indicator in acute myeloid leukemia.

Chromosomal aberrations are useful in assessing treatment options and clinical outcomes of acute myeloid leukemia (AML) patients. However, 40 ∼ 50% of the AML patients showed no chromosomal abnormalities, i.e., with normal cytogenetics aka the CN-AML patients. Testing of molecular aberrations such a...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Xiaodong Lyu, Yaping Xin, Ruihua Mi, Jing Ding, Xianwei Wang, Jieying Hu, Ruihua Fan, Xudong Wei, Yongping Song, Richard Y Zhao
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2014
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/2c20a92c0ec54df1ab7d862bd272c924
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2c20a92c0ec54df1ab7d862bd272c924
record_format	dspace
spelling	oai:doaj.org-article:2c20a92c0ec54df1ab7d862bd272c9242021-11-18T08:26:24ZOverexpression of Wilms tumor 1 gene as a negative prognostic indicator in acute myeloid leukemia.1932-620310.1371/journal.pone.0092470https://doaj.org/article/2c20a92c0ec54df1ab7d862bd272c9242014-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24667279/?tool=EBIhttps://doaj.org/toc/1932-6203Chromosomal aberrations are useful in assessing treatment options and clinical outcomes of acute myeloid leukemia (AML) patients. However, 40 ∼ 50% of the AML patients showed no chromosomal abnormalities, i.e., with normal cytogenetics aka the CN-AML patients. Testing of molecular aberrations such as FLT3 or NPM1 can help to define clinical outcomes in the CN-AML patients but with various successes. Goal of this study was to test the possibility of Wilms' tumor 1 (WT1) gene overexpression as an additional molecular biomarker. A total of 103 CN-AML patients, among which 28% had overexpressed WT1, were studied over a period of 38 months. Patient's response to induction chemotherapy as measured by the complete remission (CR) rate, disease-free survival (DFS) and overall survival (OS) were measured. Our data suggested that WT1 overexpression correlated negatively with the CR rate, DFS and OS. Consistent with previous reports, CN-AML patients can be divided into three different risk subgroups based on the status of known molecular abnormalities, i.e., the favorable (NPM1(mt)/no FLT3(ITD)), the unfavorable (FLT3(ITD)) and the intermediate risk subgroups. The WT1 overexpression significantly reduced the CR, DFS and OS in both the favorable and unfavorable groups. As the results, patients with normal WT1 gene expression in the favorable risk group showed the best clinical outcomes and all survived with complete remission and disease-free survival over the 37 month study period; in contrast, patients with WT1 overexpression in the unfavorable risk group displayed the worst clinical outcomes. WT1 overexpression by itself is an independent and negative indicator for predicting CR rate, DFS and OS of the CN-AML patients; moreover, it increases the statistical power of predicting the same clinical outcomes when it is combined with the NPM1(mt) or the FLT3(ITD) genotypes that are the good or poor prognostic markers of CN-AML.Xiaodong LyuYaping XinRuihua MiJing DingXianwei WangJieying HuRuihua FanXudong WeiYongping SongRichard Y ZhaoPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 9, Iss 3, p e92470 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Xiaodong Lyu Yaping Xin Ruihua Mi Jing Ding Xianwei Wang Jieying Hu Ruihua Fan Xudong Wei Yongping Song Richard Y Zhao Overexpression of Wilms tumor 1 gene as a negative prognostic indicator in acute myeloid leukemia.
description	Chromosomal aberrations are useful in assessing treatment options and clinical outcomes of acute myeloid leukemia (AML) patients. However, 40 ∼ 50% of the AML patients showed no chromosomal abnormalities, i.e., with normal cytogenetics aka the CN-AML patients. Testing of molecular aberrations such as FLT3 or NPM1 can help to define clinical outcomes in the CN-AML patients but with various successes. Goal of this study was to test the possibility of Wilms' tumor 1 (WT1) gene overexpression as an additional molecular biomarker. A total of 103 CN-AML patients, among which 28% had overexpressed WT1, were studied over a period of 38 months. Patient's response to induction chemotherapy as measured by the complete remission (CR) rate, disease-free survival (DFS) and overall survival (OS) were measured. Our data suggested that WT1 overexpression correlated negatively with the CR rate, DFS and OS. Consistent with previous reports, CN-AML patients can be divided into three different risk subgroups based on the status of known molecular abnormalities, i.e., the favorable (NPM1(mt)/no FLT3(ITD)), the unfavorable (FLT3(ITD)) and the intermediate risk subgroups. The WT1 overexpression significantly reduced the CR, DFS and OS in both the favorable and unfavorable groups. As the results, patients with normal WT1 gene expression in the favorable risk group showed the best clinical outcomes and all survived with complete remission and disease-free survival over the 37 month study period; in contrast, patients with WT1 overexpression in the unfavorable risk group displayed the worst clinical outcomes. WT1 overexpression by itself is an independent and negative indicator for predicting CR rate, DFS and OS of the CN-AML patients; moreover, it increases the statistical power of predicting the same clinical outcomes when it is combined with the NPM1(mt) or the FLT3(ITD) genotypes that are the good or poor prognostic markers of CN-AML.
format	article
author	Xiaodong Lyu Yaping Xin Ruihua Mi Jing Ding Xianwei Wang Jieying Hu Ruihua Fan Xudong Wei Yongping Song Richard Y Zhao
author_facet	Xiaodong Lyu Yaping Xin Ruihua Mi Jing Ding Xianwei Wang Jieying Hu Ruihua Fan Xudong Wei Yongping Song Richard Y Zhao
author_sort	Xiaodong Lyu
title	Overexpression of Wilms tumor 1 gene as a negative prognostic indicator in acute myeloid leukemia.
title_short	Overexpression of Wilms tumor 1 gene as a negative prognostic indicator in acute myeloid leukemia.
title_full	Overexpression of Wilms tumor 1 gene as a negative prognostic indicator in acute myeloid leukemia.
title_fullStr	Overexpression of Wilms tumor 1 gene as a negative prognostic indicator in acute myeloid leukemia.
title_full_unstemmed	Overexpression of Wilms tumor 1 gene as a negative prognostic indicator in acute myeloid leukemia.
title_sort	overexpression of wilms tumor 1 gene as a negative prognostic indicator in acute myeloid leukemia.
publisher	Public Library of Science (PLoS)
publishDate	2014
url	https://doaj.org/article/2c20a92c0ec54df1ab7d862bd272c924
work_keys_str_mv	AT xiaodonglyu overexpressionofwilmstumor1geneasanegativeprognosticindicatorinacutemyeloidleukemia AT yapingxin overexpressionofwilmstumor1geneasanegativeprognosticindicatorinacutemyeloidleukemia AT ruihuami overexpressionofwilmstumor1geneasanegativeprognosticindicatorinacutemyeloidleukemia AT jingding overexpressionofwilmstumor1geneasanegativeprognosticindicatorinacutemyeloidleukemia AT xianweiwang overexpressionofwilmstumor1geneasanegativeprognosticindicatorinacutemyeloidleukemia AT jieyinghu overexpressionofwilmstumor1geneasanegativeprognosticindicatorinacutemyeloidleukemia AT ruihuafan overexpressionofwilmstumor1geneasanegativeprognosticindicatorinacutemyeloidleukemia AT xudongwei overexpressionofwilmstumor1geneasanegativeprognosticindicatorinacutemyeloidleukemia AT yongpingsong overexpressionofwilmstumor1geneasanegativeprognosticindicatorinacutemyeloidleukemia AT richardyzhao overexpressionofwilmstumor1geneasanegativeprognosticindicatorinacutemyeloidleukemia
_version_	1718421792116178944

Overexpression of Wilms tumor 1 gene as a negative prognostic indicator in acute myeloid leukemia.

Ejemplares similares